Strategic partnership Leverage the existing exclusive distribution agreement with MedMira for COVID-19 antibody tests to explore broader diagnostic collaborations, enabling cross-sell opportunities with complementary rapid test technologies.

Niche focus Target emerging and hard-to-diagnose disease populations where rapid diagnostics are critical, positioning WebbDX as a specialized provider of intersectional biotech, immunochemistry, and AI-enabled solutions for early detection.

Growth potential With a small team and sub-$1M revenue, pursue scalable partnerships with larger healthcare distributors or OEMs to accelerate market reach, leveraging their nimble operations and cutting-edge tech stack to differentiate offerings.

Tech enablement Emphasize AI-driven diagnostic capabilities and clinical science expertise in sales pitches to larger clinics, hospital networks, and telehealth platforms seeking advanced rapid testing and analytics integration.

Market alignment Capitalize on rising demand for rapid point-of-care diagnostics and serology tests by aligning product messaging with regulatory approvals, deployment at clinics and urgent care centers, and potential public health partnerships.